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Influenzalike
Illness Among
Homeless Persons
To the Editor: We report rates of
influenzalike illness (ILI) and influen-
za vaccination among homeless per-
sons at 3 shelter clinics in New York
City examined from 1997 through
2004. Little is understood regarding
the prevalence and transmission of
influenza among the homeless (1).
Further inquiry on this topic is timely
because of concern over a possible
influenza pandemic, because of US
goals to increase vaccination rates
among high-risk groups (2), and
because of the potential threat to per-
sons who live and work in shelters.
Homeless shelters are paradigmatic
congregate settings and thus likely
sites for transmission of airborne
pathogens such as influenza viruses
and tubercle bacilli, shown in part by
numerous tuberculosis outbreaks
among the homeless (3).
Homeless persons experience high
rates of pneumonia (4) and related
death (5,6). This outcome indicates
that the homeless also have high rates
of influenza because pneumonia is a
common complication of influenza.
Depending upon patient’s age and
sex, death rates attributed to pneumo-
nia or influenza among homeless
adults ranged from 1.6 to 6.3 (95%
confidence interval 0.4–24.1) in one
study (7). The New York City
Departments of Health and Mental
Hygiene and Homeless Services
reported in December 2005 that 1% of
hospitalizations and 3.4% of deaths of
homeless adults in New York City
from 2001 to 2003 were caused by
influenza or pneumonia (8).
We analyzed 4,319 medical charts
of persons who received medical
services in 3 New York City homeless
shelter clinics during influenza sea-
sons (i.e., October 1 through May 30)
from 1997 through 2004. This study
was approved by the St. Vincent’s
Hospital Research Committee and
Institutional Review Board. This
analysis identified 59 recorded cases
of ILI, defined as temperature >100°F
(37.8°C) and cough, sore throat, or
both (Table). ILI is accepted as an
indicator of influenza by the Centers
for Disease Control and Prevention
and others (9).
The overall medical chart review
also showed that less than one fourth
of all persons examined and one third
of those >65 years of age had evi-
dence of influenza vaccination noted
in their charts. Vaccinations are avail-
able from many sources, but those
given at shelter clinics accounted for a
large percentage, and vaccination
rates varied widely by homeless shel-
ter clinic site.
This study has some limitations.
Because vaccinations are offered at
numerous health centers, rates of vac-
cination based on the medical charts
we studied may be underestimated.
Moreover, since only those homeless
persons at shelters who attended the
medical clinic provided data, the find-
ings cannot be used to make general-
izations regarding ILI or influenza
vaccination rates among the general
population of the shelters. None-
theless, these numbers can serve as a
basis for more rigorous inquiry.
The implementation of an appro-
priate public health response is critical
in maintaining the health of homeless
persons. Controlling influenza trans-
mission within shelters may benefit
the broader public in the same way
that reducing the rates of tuberculosis
among homeless persons is regarded
as essential in preventing transmission
to the general population.
The decision to receive an influen-
za vaccination is influenced by many
factors. These factors include concern
with related side effects, belief that
the vaccine is not required, previous
bad reactions, dislike of injections,
and doubts about vaccine efficacy
(10). Understanding how these factors
affect vaccination rates among the
homeless would be valuable in plan-
ning healthcare interactions and qual-
ity improvements. Similarly, since the
New York City Departments of Health
and Mental Hygiene and Homeless
Services recommend that influenza
immunizations be provided to all
sheltered homeless adults and shelter
staff (8), further inquiry would help
determine the risk-benefit balance of
such an approach.
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Human West Nile
Virus Infection,
Catalonia, Spain
To the Editor: West Nile virus
(WNV) is a mosquitoborne flavivirus
that is widespread in Africa, the
Middle East, Asia, and southern
Europe, where it causes outbreaks and
sporadic cases of the disease. It has
become an emergent disease in North
America, where it was detected for
the first time in 1999 and became epi-
demic shortly thereafter (1). Although
WNV was initially considered to have
a minor health effect in the
Mediterranean basin, human and
equine outbreaks reported in the last
decade in different countries (2–5)
have made WNV infections a public
health concern.
The epidemiology of WNV in
Europe differs from that in America
and has only been associated with
nonrecurrent, sporadic outbreaks. The
reasons for this difference are contro-
versial; it may be due to environmen-
tal factors, reservoirs, or even mos-
quito vectors. In Spain, neither equine
nor human WNV cases have been
reported. However, some human sero-
surveys that used hemagglutination
inhibition suggested that WNV or
closely related flaviviruses circulated
during the 1970s in the Ebro delta and
areas in Spain (6,7). The Ebro delta, a
wetland in Catalonia, in the northeast
of Spain, is a stopping-off point for
birds migrating between regions of
Africa and Europe where different
WNV vectors and reservoirs have
been identified. The delta could be
considered a high-risk area for WNV
and other arthropodborne virus infec-
tions.
To evaluate WNV seroprevalence
in the human population of the Ebro
delta, a survey was conducted in
2001. After obtaining informed con-
sent, 992 serum samples were
obtained from inhabitants of the area.
The population studied was represen-
tative of the whole area and was strat-
ified by sex and age.
Anti-WNV immunoglobulin G
(IgG) antibodies were determined by
using an in-house indirect enzyme-
linked immunosorbent assay
(ELISA), as previously described (8).
Results were classified as the sample
absorbance/positive control absor-
bance ratio. Samples showing ratio
values >0.2 were tested for WNV IgG
and IgM by using an indirect and a
µ-chain capture ELISA, respectively
(Focus Technologies, Cypress, CA,
USA), and an in-house microneutral-
ization test.
For the microneutralization test,
samples were tested in duplicate and
assayed twice. Twofold dilutions (25
µL) of the samples (1:16–1:256 dilu-
tions) were assayed by using 100
TCID50 (50% tissue culture infectious
dose) of West Nile Eg-101 reference
strain in 96-well tissue culture plates
with Vero cells and after 7 days of
incubation at 37°C and 5% CO2.
Thirty-eight samples showed IgG
ratios >0.2 by the in-house ELISA. Of
these, 12 showed WNV IgG, and 1
was positive for WNV IgM and IgG,
according to the Focus assays. Two
samples showed positive neutralizing
activity, with titers of 32 and 256. The
highest titer was shown by the sample
that yielded positive levels of both
IgM and IgG in the ELISA, which
suggests recent WNV infection.
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